医学
身材矮小
生长激素缺乏
生长激素
骨龄
内科学
特发性矮身高
内分泌学
儿科
生长激素治疗
体质指数
激素
垂体机能减退
人生长激素
作者
Lucia Schena,Cristina Meazza,Sara Pagani,Valeria Paganelli,Elena Bozzola,Carmine Tinelli,Fabio Buzi,Mauro Bozzola
标识
DOI:10.1515/jpem-2016-0297
摘要
Abstract Background: In recent years, several studies have been published showing different responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of the present study was to investigate whether non-growth-hormone-deficient (non-GHD) short children could benefit from long-term GH treatment as GHD patients. Methods: We enrolled 22 prepubertal children and 22 age- and sex-matched GHD patients, with comparable height, body mass index (BMI), bone age, and insulin-like growth factor 1 (IGF-I) circulating levels. The patients were treated with recombinant human GH (rhGH) and followed until they reach adult height. Results: During GH treatment, the two groups grew in parallel, reaching the same final height-standard deviation score (SDS) and the same height gain. On the contrary, we found significantly lower IGF-I serum concentrations in non-GHD patients than in GHD ones, at the end of therapy (p=0.0055). Conclusions: In our study, the response to GH treatment in short non-GHD patients proved to be similar to that in GHD ones. However, a careful selection of short non-GHD children to be treated with GH would better justify the cost of long-term GH therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI